Parameter
| Biomarker | PD-L1 | Full name | Programmed death-ligand 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prediction, prognosis |
| Disease | Cervical Cancer | Disease Subtypes | / | ||
| Organ | Cervix | Test Sample / Technology Platform | Tumor tissue (IHC, SP263/22C3/SP142 antibody) | ||
| Pathobiological Mechanisms | Combining the PD-1 receptor on the surface of T cells to inhibit T cell activation and mediate tumor immune escape. | ||||
| Clinical Availability Status | Clinical translation / Immunotherapy companion diagnostics: Some clinical trials have adopted it as a stratification criterion. | ||||
| Notes and Dynamics | The objective response rate (ORR) for PD-L1 positive (CPS ≥ 1) patients treated with PD-1 inhibitors reached 35% - 40%. | ||||